192 related articles for article (PubMed ID: 32470475)
1. Cost-effectiveness Analysis of Screening Extremely Low Birth Weight Children for Hepatoblastoma Using Serum Alpha-fetoprotein.
MacDonell-Yilmaz R; Anderson K; DeNardo B; Sprinz P; Padula WV
J Pediatr; 2020 Oct; 225():80-89.e4. PubMed ID: 32470475
[TBL] [Abstract][Full Text] [Related]
2. Serum α-fetoprotein concentration in extremely low-birthweight infants.
Maruyama K
Pediatr Int; 2017 Feb; 59(2):159-162. PubMed ID: 27400853
[TBL] [Abstract][Full Text] [Related]
3. Screening for Wilms tumor and hepatoblastoma in children with Beckwith-Wiedemann syndromes: a cost-effective model.
McNeil DE; Brown M; Ching A; DeBaun MR
Med Pediatr Oncol; 2001 Oct; 37(4):349-56. PubMed ID: 11568898
[TBL] [Abstract][Full Text] [Related]
4. Hepatoblastoma in children of extremely low birth weight: a report from a single perinatal center.
Oue T; Kubota A; Okuyama H; Kawahara H; Nara K; Kawa K; Kitajima H
J Pediatr Surg; 2003 Jan; 38(1):134-7; discussion 134-7. PubMed ID: 12592636
[TBL] [Abstract][Full Text] [Related]
5. Projected cost-effectiveness of statewide universal newborn hearing screening.
Keren R; Helfand M; Homer C; McPhillips H; Lieu TA
Pediatrics; 2002 Nov; 110(5):855-64. PubMed ID: 12415021
[TBL] [Abstract][Full Text] [Related]
6. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).
Chan K; Davis J; Pai SY; Bonilla FA; Puck JM; Apkon M
Mol Genet Metab; 2011 Nov; 104(3):383-9. PubMed ID: 21810544
[TBL] [Abstract][Full Text] [Related]
7. Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia.
Clericuzio CL; Chen E; McNeil DE; O'Connor T; Zackai EH; Medne L; Tomlinson G; DeBaun M
J Pediatr; 2003 Aug; 143(2):270-2. PubMed ID: 12970646
[TBL] [Abstract][Full Text] [Related]
8. The Utility of Serum Alpha-fetoprotein for Monitoring for Relapse of Alpha-fetoprotein-Positive Hepatoblastoma.
Davini M; Hastings C; Feusner J
J Pediatr Hematol Oncol; 2024 May; 46(4):206-210. PubMed ID: 38551915
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of newborn screening for severe combined immunodeficiency.
Van der Ploeg CPB; Blom M; Bredius RGM; van der Burg M; Schielen PCJI; Verkerk PH; Van den Akker-van Marle ME
Eur J Pediatr; 2019 May; 178(5):721-729. PubMed ID: 30805731
[TBL] [Abstract][Full Text] [Related]
10. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
[TBL] [Abstract][Full Text] [Related]
11. Defining an optimal time window to screen for hepatoblastoma in children with Beckwith-Wiedemann syndrome.
Mussa A; Duffy KA; Carli D; Ferrero GB; Kalish JM
Pediatr Blood Cancer; 2019 Jan; 66(1):e27492. PubMed ID: 30270492
[TBL] [Abstract][Full Text] [Related]
12. Relapse surveillance in AFP-positive hepatoblastoma: re-evaluating the role of imaging.
Rojas Y; Guillerman RP; Zhang W; Vasudevan SA; Nuchtern JG; Thompson PA
Pediatr Radiol; 2014 Oct; 44(10):1275-80. PubMed ID: 24839140
[TBL] [Abstract][Full Text] [Related]
13. Hepatoblastoma in a child of extremely low birth weight.
Jaing TH; Hung IJ; Lin JN; Lien RI; Hsueh C; Lu CS
Am J Perinatol; 2002 Apr; 19(3):149-53. PubMed ID: 12012290
[TBL] [Abstract][Full Text] [Related]
14. Hepatoblastoma incidence in the United States from 1973 to 1992.
Ross JA; Gurney JG
Med Pediatr Oncol; 1998 Mar; 30(3):141-2. PubMed ID: 9434819
[TBL] [Abstract][Full Text] [Related]
15. α-Fetoprotein assay on dried blood spot for hepatoblastoma screening in children with overgrowth-cancer predisposition syndromes.
Mussa A; Pagliardini S; Pagliardini V; Molinatto C; Baldassarre G; Corrias A; Silengo MC; Ferrero GB
Pediatr Res; 2014 Dec; 76(6):544-8. PubMed ID: 25167201
[TBL] [Abstract][Full Text] [Related]
16. DLK1, a serum marker for hepatoblastoma in young infants.
Falix FA; Aronson DC; Lamers WH; Hiralall JK; Seppen J
Pediatr Blood Cancer; 2012 Oct; 59(4):743-5. PubMed ID: 22180200
[TBL] [Abstract][Full Text] [Related]
17. Using benefit-cost ratio to select Universal Newborn Hearing Screening test criteria.
Porter HL; Neely ST; Gorga MP
Ear Hear; 2009 Aug; 30(4):447-57. PubMed ID: 19455038
[TBL] [Abstract][Full Text] [Related]
18. Estimated Cost-effectiveness of Newborn Screening for Congenital Cytomegalovirus Infection in China Using a Markov Model.
Chen K; Zhong Y; Gu Y; Sharma R; Li M; Zhou J; Wu Y; Gao Y; Qin G
JAMA Netw Open; 2020 Dec; 3(12):e2023949. PubMed ID: 33275150
[TBL] [Abstract][Full Text] [Related]
19. The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment: Mexico and the United States.
Rothschild MI; Russ R; Brennan KA; Williams CJ; Berrones D; Patel B; Martinez-Castellanos MA; Fernandes A; Hubbard GB; Chan RVP; Yang Z; Olsen TW
Am J Ophthalmol; 2016 Aug; 168():110-121. PubMed ID: 27130372
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of neonatal intensive care for extremely low birth weight infants in Victoria over two decades: II. Efficiency.
Doyle LW;
Pediatrics; 2004 Mar; 113(3 Pt 1):510-4. PubMed ID: 14993542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
